5 Biotech Stocks Worth Adding to Your Portfolio in 2025
Portfolio Pulse from
The Zacks Biomedical and Genetics industry is expected to maintain momentum in 2025 due to new drug approvals and pipeline progress. Companies like INCY, BMRN, EXEL, HALO, and BPMC are well-positioned in this volatile sector.
January 14, 2025 | 4:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioMarin Pharmaceutical Inc. (BMRN) is expected to benefit from new drug approvals and pipeline advancements in 2025.
BMRN is mentioned as a company with potential growth due to new drug approvals and pipeline progress.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Blueprint Medicines Corporation (BPMC) is well-positioned for growth in 2025 with a strong pipeline and potential new drug approvals.
BPMC is highlighted for its strong pipeline and potential new drug approvals, indicating growth potential.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Exelixis, Inc. (EXEL) is positioned for growth in 2025 with a strong pipeline and potential new drug approvals.
EXEL is highlighted for its strong pipeline and potential new drug approvals, indicating growth potential.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Halozyme Therapeutics, Inc. (HALO) is expected to see growth in 2025 due to its strong portfolio and pipeline progress.
HALO is mentioned as having a strong portfolio and pipeline progress, which are key for growth in the biotech sector.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Incyte Corporation (INCY) is well-positioned for growth in 2025 due to its strong portfolio and pipeline progress in the biotech sector.
INCY is highlighted as having a strong portfolio and pipeline progress, which are key factors for growth in the biotech sector.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80